Updates in the Treatment of Patients With Colorectal Cancer

Abstract

A number of assays are now available to estimate the prognosis of early-stage colorectal cancer, including multigene assays, the Immunoscore, and circulating tumor DNA (ctDNA). Although the results of these assays may provide prognostic information regarding the risk for recurrence, their use as a predictive assay has not yet been validated. Therefore, although these assays may be useful for prognostication, further validation would be required to include in the NCCN Guidelines. For the treatment of metastatic colorectal cancer, major advances have included the use of checkpoint inhibition in metastatic disease. Studies are currently underway to further define their optimal use.

Disclosures: Dr. Krishnamurthi has disclosed receiving grant/research support from Aravive, Bristol-Myers Squibb Company, and Natera.

Correspondence: Smitha S. Krishnamurthi, MD, Cleveland Clinic, 9500 Euclid Avenue, CA5-068, Cleveland, OH 44195. Email: krishns3@ccf.org
  • 1.

    Niedzwiecki D, Frankel WL, Venook AP, et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (Alliance). J Clin Oncol 2016;34:30473053.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:39373944.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391:21282139.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Pagès F, Mlecnik B, Marliot F, et al. . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391:212–-2139.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Sinicrope FA, Shi Q, Hermitte F, et al. Contribution of Immunoscore and molecular features to survival prediction in stage III colon cancer. JNCI Cancer Spectr 2020;4:pkaa023.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Pagès F, André T, Taieb J, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol 2020;31:921929.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 2019;5:11241131.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res 2022;28:507517.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Diehn M, Alizadeh AA, Adams HP, et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA) [abstract ]. J Clin Oncol 2017;35(Suppl):Abstract 3591.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res 2021;27:55865594.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kotaka M, Shirasu H, Wantanbe J, et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan [abstract ]. J Clin Oncol 2022;40(Suppl 4):Abstract 9.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Andre T, De Braud FG, Jimenez-Rodriguez B, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: a post-hoc subgroup analysis of patients with colorectal cancer [abstract ]. J Clin Oncol 2022; 40(Suppl 4):Abstract 201.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:22072218.

  • 15.

    Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/ microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773779.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Lenz HJ, Van Cutsem E, Limon ML, et al. First-Line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol 2022;40:161170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Cohen R, Meurisse A, Pudiarz T, et al. One-year duration of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: long-term follow-up of the GERCOR NIPICOL phase II study [abstract ]. J Clin Oncol 2022;40(Suppl):Abstract 13.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1463 1463 1463
PDF Downloads 875 875 875
EPUB Downloads 0 0 0